Studies show advances in gastrointestinal cancer treatments
Phase III data reported at ESMO 2012
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Phase III data reported at ESMO 2012
ESMO 2012 emphasises palliative care: 16 new ESMO Designated Centres of Integrated Oncology and Palliative Care honoured New research providing snap-shot of palliative care in Italy
Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer, EGFR status may help select patients who will benefit most
Debate at ESMO 2012 Congress focuses on whether there is enough evidence to start using aspirin to reduce the risk of colorectal cancer
Where are the most promising developments from first-in-human studies?
Landmark global survey reveals major shortcomings in many countries around the world
Long awaited results constitute a further milestone
The first ever estimate of the economic burden of cancer in Europe shows that it exceeds 124 billion euros
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.